Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | MicrobiomeTrials← Back to trialsNCT07562152
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2028-06
Enrollment target: 510 participants Locations- City of Hope, Phoenix, Arizona, United States
- City of Hope, Duarte, California, United States
- Medical Oncology Hematology Consultants, Newark, Delaware, United States
- Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States
- Florida Cancer Specialists - South, Sarasota, Florida, United States
- Florida Cancer Specialists - North, St. Petersburg, Florida, United States
- Florida Cancer Specialists - East, West Palm Beach, Florida, United States
- Piedmont Healthcare, Atlanta, Georgia, United States
- Illinois Cancer Specialists, Arlington Heights, Illinois, United States
- City of Hope, Chicago, Illinois, United States
- OSF Medical Center, Peoria, Illinois, United States
- Maryland Oncology, Columbia, Maryland, United States
- Missouri Cancer Associates, Columbia, Missouri, United States
- Comprehensive Cancer Centers, Las Vegas, Nevada, United States
- Regional Cancer Care, Belleville, New Jersey, United States
- NYU Langone Health, New York, New York, United States
Other microbiome trials you might be interested in
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid TumorUrinary Bladder NeoplasmTriple Negative Breast CancerNon-small Cell Lung CancerEsophageal CancerPancreatic CancerOvarian CancerCervical CancerHead and Neck Squamous Cell CarcinomaProstate CancerRenal Pelvis CancerBladder Cancer
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in particip…
Duarte, United StatesEst. completion May 2027
Taylor Cancer Research Center, Maumee, Ohio, United StatesWillamette Valley Cancer Institute, Eugene, Oregon, United StatesThomas Jefferson University, Philadelphia, Pennsylvania, United StatesWest Cancer Center, Germantown, Tennessee, United StatesSarah Cannon Research Institute, Nashville, Tennessee, United StatesTexas Oncology - West Texas, Abilene, Texas, United StatesTexas Oncology - Austin, Austin, Texas, United StatesTexas Oncology - San Antonio, San Antonio, Texas, United StatesTexas Oncology Gulf Coast, Webster, Texas, United StatesBlue Ridge Cancer Care, Blacksburg, Virginia, United StatesVirginia Cancer Specialists, Fairfax, Virginia, United StatesNorthwest Cancer Specialists, Vancouver, Washington, United StatesCalvary Mater Newcastle, Waratah, New South Wales, AustraliaIcon Cancer Centre - Chermside, Chermside, Queensland, AustraliaPancreas CancerOligometastatic
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized …
Camden, United StatesEst. completion Jun 29, 2029
Advanced/Metastatic Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design…
Los Angeles, United StatesEst. completion Jun 2028